Maintenance olaparib in Asian patients with germline BRCA-mutated metastatic pancreatic cancer

被引：0

作者：

Oh, Do-Youn ^{[1
]}

Park, Joon Oh ^{[2
]}

Kindler, Hedy L. ^{[3
]}

Hammel, Pascal ^{[4
]}

Reni, Michele ^{[5
]}

Van Cutsem, Eric ^{[6
]}

Macarulla, Teresa ^{[7
]}

Hall, Michael J. ^{[8
]}

Arnold, Dirk ^{[9
]}

Reinacker-Schick, Anke ^{[10
]}

Tortora, Giampaolo ^{[11
]}

Algul, Hana ^{[12
]}

O'Reilly, Eileen M. ^{[13
]}

McGuiness, David ^{[14
]}

Liu, Yu-Zhen ^{[14
]}

Cui, Karen ^{[15
]}

Schlienger, Katia ^{[16
]}

Locker, Gershon Y. ^{[15
]}

Golan, Talia ^{[17
]}

机构：

[1] Seoul Natl Univ, Coll Med, Canc Res Inst, Seoul Natl Univ Hosp, Seoul, South Korea

[2] Sungkyunkwan Univ, Samsung Med Ctr, Sch Med, Seoul, South Korea

[3] Univ Chicago, Chicago, IL 60637 USA

[4] Univ Paris VII, Hop Beaujon Clichy, Paris, France

[5] IRCCS Osped San Raffaele Sci Inst, Milan, Italy

[6] Katholieke Univ Leuven, Univ Hosp Gasthuisberg, Leuven, Belgium

[7] Vall Hebron Univ Hosp, Inst Oncol, Barcelona, Spain

[8] Fox Chase Canc Ctr, Philadelphia, PA USA

[9] Asklepios Tumorzentrum Hamburg Asklepios Klin Al, Hamburg, Germany

[10] Ruhr Univ Bochum, St Josef Hosp, Bochum, Germany

[11] Fdn Policlin Gemelli IRCCS, Med Oncol Unit, Rome, Italy

[12] Tech Univ Munich, Klin Rechts Isar, Munich, Germany

[13] Memorial Sloan Kettering Canc Ctr, New York, NY USA

[14] AstraZeneca, Cambridge, England

[15] AstraZeneca, Gaithersburg, MD USA

[16] Merck & Co Inc, Kenilworth, NJ USA

[17] Tel Aviv Univ, Sheba Med Ctr, Inst Oncol, Tel Aviv, Israel

来源：

ANNALS OF ONCOLOGY | 2021年 / 32卷

关键词：

D O I：

10.1016/j.annonc.2021.05.643

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

MO31-6

引用

页码：S319 / S319

页数：1

共 50 条

[41] Leptomeningeal carcinomatosis in BRCA-mutated pancreatic cancer.
Slostad, Jessica Anne
Hallemeier, Christopher Leigh
Bamlet, William R.
Couch, Fergus
McWilliams, Robert R.
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04)
[42] Extended overall survival results from the POLO study of active maintenance olaparib in patients with metastatic pancreatic cancer and a germline BRCA mutation
Hammel, P.
Golan, T.
Reni, M.
Van Cutsem, E.
Macarulla Mercade, T.
Hall, M.
Park, J. O.
Hochhauser, D.
Arnold, D.
Oh, D-Y.
Reinacher-Schick, A.
Tortora, G.
Alguel, H.
O'Reilly, E.
Sharan, K.
Ou, X.
Cui, K. Y.
Locker, G.
Kindler, H.
ANNALS OF ONCOLOGY, 2022, 33 (07) : S1137 - S1137
[43] An open-label, phase II basket study of olaparib and durvalumab (MEDIOLA): Updated results in patients with germline BRCA-mutated (gBRCAm) metastatic breast cancer (MBC)
Domchek, S. M.
Postel-Vinay, S.
Im, S-A
Park, Y. Hee
Delord, J-P
Italiano, A.
Alexandre, J.
You, B.
Bastian, S.
Krebs, M. G.
Waqar, S.
Lanasa, M.
Angell, H. K.
Tang, M.
Gresty, C.
Opincar, L.
Herbolsheimer, P.
Kaufman, B.
CANCER RESEARCH, 2019, 79 (04)
[44] FDA Approval Summary: Olaparib in Combination With Abiraterone for Treatment of Patients With BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer
Fallah, Jaleh
Xu, Jianjin
Weinstock, Chana
Brave, Michael H.
Bloomquist, Erik
Fiero, Mallorie H.
Schaefer, Timothy
Pathak, Anand
Abukhdeir, Abdelrahmman
Bhatnagar, Vishal
Chiu, Haw-Jyh
Ricks, Tiffany
John, Christy
Hamed, Salaheldin
Lee, Christal
Pierce, William F.
Kalavar, Shyam
Philip, Reena
Tang, Shenghui
Amiri-Kordestani, Laleh
Pazdur, Richard
Kluetz, Paul G.
Suzman, Daniel
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (05) : 605 - 613
[45] OCTOVA: A randomised phase II trial of olaparib, chemotherapy, or olaparib and cediranib in patients with BRCA-mutated platinumresistant ovarian cancer
Nicum, S.
Strauss, V. Y.
McGregor, N.
McNeish, I.
Roux, R.
Hall, M.
Michael, A.
Roberts, C.
ANNALS OF ONCOLOGY, 2017, 28
[46] Maintenance Olaparib for Metastatic Pancreatic Cancer
Puccini, Alberto
Bregni, Giacomo
Sciallero, Stefania
NEW ENGLAND JOURNAL OF MEDICINE, 2019, 381 (15): : 1491 - 1492
[47] Adverse events (AEs) with maintenance olaparib in patients with a germline BRCA mutation (gBRCAm) and metastatic pancreatic cancer (mPaC): Phase III POLO trial
Algul, H.
Reni, M.
Kindler, H. L.
Hammel, P.
Van Cutsem, E.
Macarulla, T.
Hall, M. J.
Park, J. O.
Hochhauser, D.
Arnold, D.
Oh, D-Y
Reinacher-Schick, A.
Tortora, G.
O'Reilly, E.
McGuiness, D.
Cui, K.
Schlienger, K.
Locker, G.
Golan, T.
ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 216 - 216
[48] POLO: Time to treatment discontinuation and subsequent therapies following maintenance olaparib for patients (pts) with a germline BRCA mutation and metastatic pancreatic cancer (mPC)
Van Cutsem, E.
Golan, T.
Hammel, P.
Reni, M.
Macarulla, T.
Hall, M. J.
Park, J. O.
Hochhauser, D.
Arnold, D.
Oh, D-Y.
Reinacher-Schick, A.
Tortora, G.
Alguel, H.
O'Reilly, E. M.
McGuinness, D.
Cui, K. Y.
Schlienger, K.
Locker, G. Y.
Kindler, H. L.
ANNALS OF ONCOLOGY, 2019, 30 : 264 - +
[49] Extended Overall Survival Results from the POLO Study of active Maintenance Therapy with Olaparib in Patients with metastatic Pancreatic Cancer and a Germline BRCA Mutation
Arnold, D.
Golan, T.
Hammel, P.
Reni, M.
Van Cutsem, E.
Macarulla, T.
Hall, J. M.
Park, Oh J.
Hochhauser, D.
Oh, D. -Y.
Reinacher-Schick, A.
Tortora, G.
Alguel, H.
O'Reilly, M. E.
Kindler, L. H.
Sharan, K.
Ou, X.
Cui, K.
Locker, Y. G.
ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 2) : 224 - 225
[50] Adverse events (AEs) with maintenance olaparib in patients with a germline BRCA mutation (gBRCAm) and metastatic pancreatic cancer (mPaC): Phase III POLO trial
Reni, Michele
Kindler, Hedy L.
Hammel, Pascal
Van Cutsem, Eric
Macarulla, Teresa
Hall, Michael J.
Park, Joon Oh
Hochhauser, Daniel
Arnold, Dirk
Oh, Do-Youn
Reinacher-Schick, Anke C.
Tortora, Giampaolo
Algul, Hana
O'Reilly, Eileen Mary
McGuinness, David
Cui, Karen
Schlienger, Katia
Locker, Gershon Y.
Golani, Talia
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)

← 1 2 3 4 5 →